Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA

Castration-resistant Prostate Cancer Clinical Trial

— BARRIER-P  

Official title:

An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02429193
• Other study ID #: BARRIER-P
• Status: Completed
• Phase: Phase 2
• Start date: March 2016
• Est. completion date: September 1, 2019

Study information

• Verified date: January 2020
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label phase 2 multi-center study of abiraterone and enzalutamide in men with castration-resistant prostate cancer. Sixteen patients will be enrolled over 18 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: September 1, 2019
• Est. primary completion date: September 1, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with histologically or cytologically confirmed prostate cancer

• Able to read and understand the consent form, either alone or with the aid of a translator

• Surgically or medically castrated, with testosterone levels of < 50 ng/dL (< 2.0 nmol/L). If the patient is being treated with luteinizing hormone-releasing hormone (LHRH) agonists (patients who have not undergone orchiectomy), they must remain on continuous androgen suppression therapy throughout the study

• Patients receiving bone-targeted therapies must be on stable doses for at least 4 weeks prior to enrollment

• Historical frozen/paraffin-embedded diagnostic tissue specimens are available for analysis (i.e. radical prostatectomy or biopsy tissue)

• Documented metastatic disease by positive bone scan or metastatic lesions (on CT or MRI) that can be biopsied with an anticipated minimum of 4 cores, as assessed by the local radiologist

• prostate cancer progression at study entry defined as one or more of the following criteria: i. Rising PSA: minimum of two rising PSA levels with an interval of = 1 week between each determination ii. Soft tissue disease progression, as defined by RECIST 1.1 iii. Bone disease progression, as defined by PCWG2 with two or more new lesions on bone scan

• PSA value at screening visit = 2 µg/L (2 ng/mL)

• ECOG performance status 0-2

• Adequate organ and BM function, as defined by the following criteria:

i. absolute neutrophil count =1,500/µL ii. platelets =100,000/µL iii. total bilirubin =1.5 × institutional upper limit of normal (ULN) iv. AST(SGOT) or ALT(SGPT) =2.5 × institutional ULN v. creatinine =1.5 × institutional ULN or below

• Serum albumin = 3.0 g/dL

• Serum potassium = 3.5 mmol/L

• Haemoglobin = 10.0 g/dL, independent of transfusion

• Asymptomatic or mildly symptomatic from prostate cancer

• Life expectancy of > 6 months

• Able to swallow study drugs

• Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 13 weeks after last study drug administration

Exclusion Criteria:

• Patients with known hypersensitivity or allergy to abiraterone acetate, enzalutamide or any of their excipients.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, congestive heart failure (NYHA Class 3 or greater), cirrhosis with a Child-Pugh level of B or greater or evidence of cardiac dysfunction, unstable angina pectoris, cardiac arrhythmia, myocardial infarction within 6 months, hypotension (defined by systolic blood pressure < 86 mmHg at Screening visit), hypertension (defined by systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg at Screening visit), bradycardia (defined by < 50 beats per minute on ECG performed at screening), active peptic ulcer disease, clinically significant gastrointestinal conditions (e.g. Crohns disease, ulcerative colitis), any seizure disorder or psychiatric illness, and social situations that would limit compliance with study requirements

• Active invasive malignancy at any other site excluding squamous cell or basal cell carcinomas of the skin

• Known or suspected brain metastasis or leptomeningeal disease

• Radiotherapy within the past 4 weeks, except for low dose palliative radiation to bone of =5 fractions

• Treatment with 5-a reductase inhibitors (finasteride, dutasteride), androgen receptor antagonists (bicalutamide, nilutamide, flutamide), estrogens, cyproterone within 4 weeks of Day 1 visit

Related Conditions & MeSH terms

• Castration-resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Abiraterone + prednisone
Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)
• Enzalutamide
Enzalutamide (160 mg/day p.o.)

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre	Toronto	Ontario
Canada	British Columbia Cancer Agency, Vancouver Cancer Centre	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of participants with adverse events from the administration of abiraterone, enzalutamide, and prednisone to men with early stage prostate cancer.	The number of participants experiencing adverse events will be evaluated to determine the safety of abiraterone, enzalutamide, and prednisone treatment in men with early stage prostate cancer, .	18 months
Primary	Change in expression of androgen receptor abnormalities (e.g. ARV7, AR mutations) following abiraterone/enzalutamide treatment	The change in protein expression of androgen receptor (AR7) splice variant and AR / AR pathway mutations as a mechanism of resistance to abiraterone/enzalutamide is evaluated by measuring the difference in a quantitative immunohistochemical biomarker between assays performed before and after treatment.	18 months
Secondary	Rate of PSA increase		18 months
Secondary	Time to PSA progression	PSA progression is defined as a = 25% increase and an absolute increase of = 2 µg/L (2 ng/mL) above the nadir.	18 months